Ipamorelin
Selective Growth Hormone Secretagogue — Clean GH Pulse Without Cortisol Spike
Growth Hormone & Metabolism
Version 2025-04 · Last Reviewed April 1, 2025
About this review (v2025-04, last reviewed April 1, 2025): This review was compiled from published preclinical and clinical research, FDA regulatory documents, and compounding pharmacy guidance. No peptide vendor or manufacturer reviewed or approved this content. Read our full methodology
Educational content only. This page reflects published research and does not constitute medical advice. Peptides are not FDA-approved drugs (with limited exceptions noted). Consult a licensed healthcare provider before use. Dosing is intentionally omitted — it is determined by your provider based on individual labs and goals.
What it is
Ipamorelin is a synthetic five-amino-acid (pentapeptide) growth hormone secretagogue — meaning it stimulates the pituitary gland to release its own growth hormone (GH). It was developed in the 1990s and has been studied in clinical trials, though it was never brought to FDA approval. Its key distinction from other GH secretagogues (like GHRP-6 or hexarelin) is its selectivity: it stimulates GH release without significantly raising cortisol, prolactin, or ACTH. This selectivity profile is why it became popular in clinical practice.
Regulatory status
Not FDA-approved for any indication. Not DEA scheduled. Ipamorelin is a synthetic pentapeptide that can be compounded at licensed 503A compounding pharmacies under a physician prescription. Frequently prescribed by functional medicine physicians, anti-aging clinics, and endocrinologists for off-label use in adult GH deficiency, body composition, and recovery support.
Mechanism of Action
Ipamorelin binds selectively to the ghrelin receptor (GHS-R1a) in the pituitary gland, triggering a GH pulse. Unlike most GHRPs, it does not significantly stimulate cortisol or prolactin release, which distinguishes it from older secretagogues. The GH pulse released is physiological — the GH comes from the pituitary's own stores in a natural pulsatile pattern rather than the supraphysiological sustained elevation seen with exogenous HGH injection. Often combined with CJC-1295 (a GHRH analog) to create a synergistic 'two-signal' approach: one amplifies the GH pulse magnitude (CJC-1295), the other triggers its release (Ipamorelin).
What Research Has Explored
These are areas of published research — not personal recommendations.
Body composition
Studies suggest that stimulating endogenous GH release may support lean muscle mass maintenance and fat metabolism, particularly in adults with declining GH levels.
Context: Effects are modest compared to exogenous HGH and are dependent on overall lifestyle, diet, and training. Research in healthy adults is limited.
Post-surgical recovery
Ipamorelin was studied in a Phase IIb trial for post-operative ileus (NNZ-2566 / Helsinn 2008–2012). The study demonstrated GH release stimulation in humans.
Context: The primary endpoint of the surgical study was GI motility recovery, not body composition. Do not extrapolate surgical dosing to wellness contexts.
Sleep quality
GH is primarily secreted during slow-wave sleep. Timing ipamorelin near sleep may augment natural nocturnal GH pulses, with anecdotal reports of improved sleep quality.
Context: No formal sleep quality RCTs exist for ipamorelin specifically.
Anti-aging / longevity
Declining GH and IGF-1 levels with age are associated with reduced lean mass, increased adiposity, and reduced recovery. GH secretagogues represent a strategy to partially restore physiological GH pulsatility.
Context: Correlation does not imply causation. Whether restoring youthful GH levels extends healthspan or merely tracks it is not established in humans.
Stability & Delivery Form — Why This Matters
Most peptides are fragile molecules destroyed by stomach acid and digestive enzymes. Delivery form determines whether the peptide survives to reach your bloodstream.
Capsule / Pill Warning
Ipamorelin in capsule or pill form has no meaningful systemic bioavailability. Stomach acid and digestive enzymes destroy the peptide bonds before absorption. If a product is sold as a capsule claiming the systemic effects of the injectable form, it cannot deliver those effects. This is a red flag about the vendor's credibility.
Subcutaneous injection (lyophilized powder, reconstituted)
The only validated route. Ipamorelin is rapidly degraded by GI proteases and has negligible oral bioavailability. Subcutaneous injection provides reliable systemic delivery.
Oral capsule / tablet
Ipamorelin is a peptide — it is destroyed by stomach acid and digestive enzymes before reaching the bloodstream. Any oral product claiming systemic ipamorelin effects cannot deliver them.
Reconstitution & Storage
Reconstitute with bacteriostatic water. Refrigerate at 2–8°C after mixing. Stability approximately 20–30 days refrigerated. Do not freeze. Protect from light. Typical presentation is 2mg or 5mg lyophilized vials.
Dosing is intentionally not listed here. It is determined by your provider based on individual labs, goals, and clinical context.
Frequently Asked Questions About Ipamorelin
- What is Ipamorelin?
- Ipamorelin is a synthetic five-amino-acid (pentapeptide) growth hormone secretagogue — meaning it stimulates the pituitary gland to release its own growth hormone (GH). It was developed in the 1990s and has been studied in clinical trials, though it was never brought to FDA approval. Its key distinction from other GH secretagogues (like GHRP-6 or hexarelin) is its selectivity: it stimulates GH release without significantly raising cortisol, prolactin, or ACTH. This selectivity profile is why it became popular in clinical practice.
- What is Ipamorelin used for in research?
- Ipamorelin is well-characterized as a selective GH secretagogue in humans with a favorable cortisol-selectivity profile, but long-term body composition and wellness benefit data in non-GH-deficient adults remain limited. Research areas include: Body composition, Post-surgical recovery, Sleep quality.
- Is Ipamorelin FDA approved?
- Not FDA-approved for any indication. Not DEA scheduled. Ipamorelin is a synthetic pentapeptide that can be compounded at licensed 503A compounding pharmacies under a physician prescription. Frequently prescribed by functional medicine physicians, anti-aging clinics, and endocrinologists for off-label use in adult GH deficiency, body composition, and recovery support.
- How is Ipamorelin administered?
- Subcutaneous injection only
- What are the safety risks of sourcing Ipamorelin?
- Key risks when sourcing Ipamorelin from grey-market or research suppliers include: Endotoxin contamination in non-sterile vials is a serious risk — fever, injection site abscess, and systemic infection are documented consequences of injecting contaminated peptides.; Ipamorelin is frequently adulterated with or substituted by cheaper GHRPs (e.g., GHRP-6) that lack the same cortisol-selective profile. You may be paying for ipamorelin's selectivity but receiving a different, less selective compound.; Concentration errors are common — a 5mg vial mislabeled as 2mg fundamentally changes dosing calculations.; Lyophilized peptide vials sold by research chemical vendors may be improperly lyophilized (freeze-dried), reducing stability and potency before you receive them..
- Who should avoid or be cautious about Ipamorelin?
- Ipamorelin should be used with caution or avoided by: Active cancer or history of hormone-sensitive malignancy — GH and IGF-1 are growth factors. Elevated IGF-1 is associated with increased cancer risk in observational studies. GH secretagogues should not be used in active cancer.; Type 2 diabetes or significant insulin resistance — GH raises blood sugar. Close metabolic monitoring required.; Diabetic retinopathy — GH stimulates VEGF which may worsen retinal vascularization.; Acromegaly history — do not use any GH secretagogue..
Stay informed — get updates when we add new medications
We add new medications and supplements regularly. No spam, ever.
No spam. Unsubscribe anytime.